Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2023-02-15 00:00:00 ET · period of report 2023-02-13 · accession 0001209191-23-009694 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-15 | 2023-02-13 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.51 | +27.5K | 31.8K | +638% | +$14.0K |
| D | 2023-02-15 | 2023-02-13 | TRVI | Delfini Lisa | CFO | S - Sale+OE | $2.45 | -8,474 | 23.3K | -27% | -$20.8K |
| D | 2023-02-15 | 2023-02-13 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.00 | -27.5K | 82.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-13 | M | A | 27,500 | $0.51 | 31,812 | D | — | — | (F2) This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on February 13, 2023. |
| 2 | Common | Common Stock | 2023-02-13 | S | D | 8,474 | $2.45 | 23,338 | D | — | — | (F2) This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on February 13, 2023. |
| 3 | Derivative | Stock Option (right to buy) | 2023-02-13 | M | D | 27,500 | $0.00 | 82,500 | D | $0.51 · — to 2032-02-10 | 27,500 Common Stock | (F4) This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |